BACE Antibody Cat. No.: 2253

Figure 1 Western Blot Validation of BACE
Loading: 15 µg of lysates per lane. Antibodies: BACE (1 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. Lane A-C: human brain tissue lysate in the absence (A) or presence (B) of blocking peptide and mouse 3T3/NIH cell lysate (C). See high quality image.

Figure 2 Independent Antibody Validation (IAV) via Protein Expression Profile in Cell Lines
Loading: 15 μg of lysates per lane. Antibodies: BACE 2253 (1 μg/mL), BACE ProMab (1 μg/mL), beta-actin (1 μg/mL), and GAPDH (0.02 μg/mL), 1h incubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution. See high quality image.

Figure 3 Immunohistochemistry Validation of BACE in Mouse Brain
Immunohistochemical analysis of paraffin-embedded mouse brain tissue using anti-BACE antibody (2253) at 2.5 μg/ml. Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. See high quality image.

Figure 4 Immunofluorescence Validation of BACE in 3T3/NIH Cells
Immunofluorescent analysis of 4% paraformaldehyde-fixed mouse 3T3/NIH cells labeling BACE with 2253 at 20 μg/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (green) and DAPI staining (blue). Image showing both membrane and cytosol staining on 3T3/NIH cells. See high quality image.

Figure 5 Immunocytochemistry Validation of BACE in 3T3/NIH Cells
Immunohistochemical analysis of 3T3/NIH cells using anti-BACE antibody (2253) at 10 μg/ml. Cells was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4˚C. A goat anti-rabbit IgG H&L (HRP) at 1/250 was used as secondary. Counter stained with Hematoxylin. See high quality image.

Figure 6 KO and Overexpression Validation of BACE in Human and Mouse Brain and 293 Cells. (Singer et al., 2005)
Western blot analysis of the BACE1 (2253) antibody’s ability to recognize human and murine BACE1. The BACE1 antibody recognized both the mouse and human forms of BACE1. Lanes 1–4 are frontal cortex homogenates from human and mouse brains. Lane 1 is from a neurologically unimpaired aged human control case, lane 2 from a BACE1-deficient mouse, lane 3 from a nontransgenic mouse and lane 4 from hBACE1 transgenic mouse. Lanes 5–7 are lysates from HEK293T cells transfected with a plasmid vector expressing eGFP, mBACE1 and hBACE1, respectively. See high quality image.

Figure 7 KD Validation of BACE in Mouse Brain (Singer et al., 2005)
Characterization of the effects of lenti-siBACE1-6 expression in the brains of APP transgenic mice. (a–d) Anti-eGFP immunoreactivity in the hippocampus (the injection site) shows comparable and consistent expression of lenti-siRNA constructs in the dentate gyrus (dg) and stratus polymorphus (sp). (e) Anti-BACE1 immunoreactivity in the hippocampus of nontransgenic mice treated with lenti-siGlut4. (f) Reduced BACE1 immunostaining in the hippocampus of nontransgenic mice treated with lenti-siBACE1-6 vector. (g) Intense BACE1 immunoreactivity in the hippocampus of APP transgenic mice treated with lenti-siGlut4. (h) Reduced BACE1 expression in APP transgenic mice treated with lenti-siBACE1-6 vector. (i,j) Anti-BACE1 reacted with pyramidal cell bodies in the neocortex, which was not injected, See high quality image.

Figure 8 KD Validation of BACE in Mouse Brain (Singer et al., 2005)
Immunolabeling patterns of BACE1 expression and the lenti-siRNA distribution. Sections from APP transgenic mice treated with the eGFPtagged lenti siRNA vectors (green) were co-immunolabeled with an antibody against BACE1 (red) and imaged with the LSCM. All sections are from the hippocampus of treated mice. (a–c) Lenti-siBACE1-6–treated mice. Areas within the hippocampus expressing the eGFP tagged vector have reduced BACE1 immunolabeling. (d–f) Mice treated with the eGFP-tagged control lenti-siGlut4 show unchanged expression of BACE1 in the hippocampus. (g–i) Mice treated with a saline vehicle show unchanged expression of BACE1 in the hippocampus.. See high quality image.

Figure 9 KO Validation of BACE in MEF Cells (Jo et al., 2010)
Wildtype and BACE −/− MEFs were exposed to HNE (15_M) for 2 h. BACE1 levels were examined by Western blot with anti-BACe antibodies (2253). See high quality image.

Figure 10 KD Validation of BACE in DRG (Hyun, 2007)
Decreased BACE1 expression in DRG following siRNA3 transfection. DRG neurons were transfected with 1 μg siRNA3 plasmid and incubated for 48 hours in 37°˚C. DRG neurons were stained for BACE1 us¬ing the Anti-BACE antibody (ProSci). (a,b) Neurons transfected with the control plas¬mid pSUPER-EGFP (green) did not display any changes in BACE1 expression (red). (c,d) DRG neurons transfected with siR¬NA3 displayed reduced BACE1 expression in the axon. See high quality image.